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Malignant transformation entails important changes in the control
of cell proliferation through the rewiring of selected signaling
pathways. Cancer cells then become very dependent on the proper
function of those pathways, and their inhibition offers therapeutic
opportunities. Here we identify the stress kinase p38α as a nononco-
genic signaling molecule that enables the progression of KrasG12V-
driven lung cancer. We demonstrate in vivo that, despite acting as a
tumor suppressor in healthy alveolar progenitor cells, p38α contributes
to the proliferation and malignization of lung cancer epithelial cells.
We show that high expression levels of p38α correlate with poor
survival in lung adenocarcinoma patients, and that genetic or chemical
inhibition of p38α halts tumor growth in lung cancer mouse models.
Moreover, we reveal a lung cancer epithelial cell-autonomous function
for p38α promoting the expression of TIMP-1, which in turn stimulates
cell proliferation in an autocrine manner. Altogether, our results sug-
gest that epithelial p38α promotes KrasG12V-driven lung cancer pro-
gression via maintenance of cellular self-growth stimulatory signals.
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Despite the many efforts invested during recent decades, thedevelopment of selective therapies remains one of the big-
gest challenges in oncology. Nowadays, lung adenocarcinomas in
advanced stages, like those driven by mutations in EGFR or
ALK, are often treated with tyrosine kinase inhibitors, but, un-
fortunately, tumors tend to become resistant in less than 1 y and
continue to progress (1, 2). The development of targeted ther-
apies for KRAS-induced lung tumors has proven especially dif-
ficult. Most of the mutated KRAS forms lack suitable pockets to
which drugs can bind in order to interfere with the oncogenic
function, and targeting some of the downstream kinases leads to
undesirable toxicities (3). An alternative approach consists of
targeting synthetic lethal partners of the mutated KRAS so that
cancer cells have their viability compromised, while the normal
cells without the mutated driver gene are not affected. When
these partners do not have oncogenic activity themselves, the
exacerbated dependency on the cancer cell for their function has
been termed “nononcogene addiction” (4). This is the case for
the transcription factor GATA2, whose deletion induces the
regression of established KRAS mutant lung tumors in mice (5).
Therefore, charting a comprehensive map of nononcogene ad-
dictions in KRAS-driven cancer may help to develop new
therapies.
The protein kinase p38α, also known as mitogen-activated
protein kinase (MAPK) 14, is normally stimulated by environ-
mental stresses and other cues, orchestrating cell responses like
proliferation, differentiation, or apoptosis depending on the
stimulus and the cell type (6, 7). In the tumor context, p38α has
been shown to interfere with malignant cell transformation in
different tissues (8–10). In particular, p38α has been reported to
suppress lung tumor formation, a function that is probably re-
lated to its ability to induce the differentiation of progenitor cells
(9). Curiously, no functionally significant genomic alterations for
p38α have been described in tumors, and there is evidence that
p38α might be constitutively phosphorylated in several cancer
types (11–13). In fact, immunohistochemistry and phosphopro-
teomic analysis have reported phosphorylated p38α in the tu-
mors from non–small-cell lung carcinoma (NSCLC) patients
(14–16). Both the scarcity of inactivating mutations and the
presence of phosphorylated p38α in tumors suggest the possi-
bility that cancer cells may use this nononcogenic signaling
pathway to facilitate tumor progression. Consistent with this
notion, epithelial cancer cells in the intestine have been shown to
exploit p38α for colon tumor maintenance in vivo (10). However,
whether p38α in epithelial cancer cells of other tissues contrib-
utes to tumor progression remains to be explored. Indeed, it is
important to contextualize the outcomes of p38α inhibition in
the different cell types of a tissue as well as the global effect of its
ubiquitous down-regulation given that the complex regulation of
survival/death signals by p38 MAPKs can result in opposite
molecular functions during tumor development, as has been
reported in UV-induced skin papillomas (17, 18) or in pancreatic
ductal adenocarcinomas (19, 20). There is evidence that p38α in
stromal cells can support lung tumorigenesis (21) and facilitate
metastatic lung cell extravasation (22), but the contribution of
p38α signaling in lung cancer epithelial cells to tumor mainte-
nance and progression has not been investigated yet to the
authors’ knowledge.
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cancer therapies. We have found that nononcogenic signaling
through p38α plays a tumor-promoting function in lung ade-
nocarcinoma epithelial cells by inducing the expression of
TIMP-1, a growth factor-like protein. We propose that p38α
inhibition could be therapeutically useful.
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In this study, we have used mouse models of KrasG12V-driven
lung cancer and spheroid cultures of lung cancer cells to show a
tumor-promoting role of epithelial p38α in established lung
tumors.
Results
p38α Expression Correlates with Malignancy and Poor Prognosis in
Lung Adenocarcinoma Patients. To investigate the role of p38α in
lung cancer, we first analyzed the expression levels of the
MAPK14 gene (encoding p38α) in a cohort of lung adenocarci-
noma patients, formed by 107 tumor samples in stages I to IV.
The levels of MAPK14 mRNA were significantly increased in the
tumors in comparison to the paired normal parenchyma (Fig.
1A). Next, in two other different cohorts of 293 and 138 samples
of tumors in stages I to III with patient follow-up data, we ob-
served that, irrespective of the tumor stage, the highest level of
MAPK14 expression correlated with a higher mortality rate (Fig.
1B), as well as with a shorter time to relapse in lung adenocar-
cinoma patients both in general (Fig. 1C) and in Kras-driven
adenocarcinoma cohorts (SI Appendix, Fig. S1 A and B). To
confirm the results obtained by analyzing public mRNA datasets,
we used antibodies against phosphorylated p38 or total p38α to
stain a human tissue microarray, which contained samples of
lung adenocarcinomas and paired adjacent normal lung tissue, as
well as normal lung tissue from patients without tumors. In line
with the mRNA analysis, we observed that lung tumors con-
tained a higher number of both phosphorylated p38- and p38α-
positive cells than the normal lung parenchyma (Fig. 1 D and E).
In parallel, we used mice expressing Kras+/FSFG12V, which
develop lung adenocarcinomas upon intratracheal administration
of adenoviruses expressing FlpO recombinase (23). Immunohisto-
chemistry analysis confirmed a significantly increased phospho-p38
staining in KrasG12V-driven lung tumors compared to the healthy
parenchyma (Fig. 1F), supporting our observations in the lung
adenocarcinoma-patient cohorts. Altogether, these results hint at the
implication of p38α in lung cancer, and suggest that its expression
levels could be used as an independent prognostic factor for lung
adenocarcinoma.
Down-Regulation of p38α in Alveolar Epithelial Progenitor Cells
Enhances KrasG12V Lung Tumorigenesis but Compromises Tumor
Progression. The correlation between MAPK14 (p38α) expres-
sion and lung tumor malignancy was unexpected, given that p38α
down-regulation has been reported to sensitize lung tissue to
KrasG12V-induced oncogenic transformation (9). When mice have
p38α ubiquitously down-regulated, they exhibit uncontrolled pro-
liferation of the alveolar epithelial type II (AE2) progenitor cells (8,
9), which can function as lung adenocarcinoma initiating cells (24,
25). However, since tumor-associated stromal cells can also regulate
tumorigenesis, we investigated the role of p38α particularly in the
alveolar progenitor cells during lung tumor development. To ad-
dress this, we induced KrasG12V expression in lungs of mice carrying
Mapk14lox/lox alleles and the surfactant protein C (SPC)-Cre-ER
transgene, in which Mapk14 can be specifically deleted in AE2
cells (Fig. 2A and SI Appendix, Fig. S1C). When these mice were
treated with tamoxifen, we observed a 25% down-regulation of the
floxed exon 2 ofMapk14 in AE2 progenitor cells both by qRT-PCR
(SI Appendix, Fig. S1D) and by using a double-fluorescent
Cre reporter (SI Appendix, Fig. S1E). Consistently, 20 wk after
KrasG12V expression, mice with AE2 cell-specific down-regulation
of p38α (p38α-ΔSPC) showed numerous lung tumors constituted by
SPC+ cells growing along the preexisting alveolar framework. The
p38α-ΔSPC tumors showed a significantly increased percentage of
proliferative cells, as marked by Ki67 staining, compared to their
wild-type (WT) counterparts (Fig. 2B). We also observed an in-
creased lung weight in p38α-ΔSPC;KrasG12V mice (SI Appendix, Fig.
S1F), as well as enhanced recruitment of immune cells in their lungs
(Fig. 2C), which correlated with increased STAT3 phosphorylation
(SI Appendix, Fig. S1G), a well-known mediator of tumor-promoting
inflammation. Accordingly, p38α-ΔSPC mice showed increased lung
tumor burden (Fig. 2D). Taken together, these results support a
tumor-suppressor role of p38α in AE2 progenitor cells of the lung
epithelia.
Surprisingly, the increased lung tumor burden observed in
KrasG12V-expressing p38α-ΔSPC mice correlated with a higher
percentage of early-stage hyperplasias versus adenomas com-
pared with the tumors in KrasG12V-expressing WT mice, in which
there were more adenomas than hyperplasias (Fig. 2E). These
observations suggest that p38α down-regulation facilitates tumor
initiation, but, once the lung epithelial cells are transformed, the
absence of p38α delays tumor progression to more advanced
stages, hinting at a possible tumor-promoting role for p38α in
lung cancer cells.
p38α Promotes KrasG12V-Driven Lung Tumor Growth. If p38α is re-
quired for lung tumor progression, the acute loss of p38α in
established tumors would be expected to hinder tumor growth.
To test this hypothesis, we first looked at the effect of the
ubiquitous down-regulation of p38α using p38α-ΔUb mice, which
bear Mapk14lox/lox alleles and the tamoxifen-inducible ubiquitin
Fig. 1. High levels of p38α expression correlate with malignancy and poor
prognosis. (A) Boxplots for expression levels of MAPK14 mRNA comparing
paired adenocarcinomas and healthy tissues (n ≥ 49 per group). a.u., arbitrary
units. (B) Kaplan–Meier plots showing a univariate analysis of overall survival of
lung adenocarcinoma patients stratified by high or low MAPK14 mRNA ex-
pression (n ≥ 39 per group). (C) Kaplan–Meier plots displaying a recurrence-free
survival over time of lung adenocarcinoma patients stratified by high or low
MAPK14 mRNA expression (n ≥ 26 per group). (D) Representative images and
boxplot of the percentage of phospho-p38+ cells in lung adenocarcinoma tu-
mors (n = 17), paired normal tissue (n = 14), and healthy lung parenchyma (n =
5) from a human tissue array. (Scale bar, 200 μm.) (E) The same samples as in D
were stained with a p38α antibody by immunofluorescence. DAPI marks nuclei.
(F) Representative image of a murine KrasG12V-driven lung tumor stained with
phospho-p38 antibody. (Scale bar, 200 μm.) The histogram shows the per-
centage of phospho-p38+ cells in tumors and in healthy lung parenchyma (n =
5 healthy tissues and n = 21 tumors from 6 different mice). Data represent
average ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

































C (UBC)-Cre-ERT2 transgene. The efficiency of p38α down-
regulation was confirmed by immunoblotting and PCR in both
whole-lung lysates and individual tumors (Fig. 3A and SI Ap-
pendix, Fig. S2 A and B). It is noteworthy that the levels of
both total p38α and phosphorylated p38 were higher in lungs
expressing oncogenic KrasG12V than in healthy lung tissue (Fig.
3A). Therefore, we induced KrasG12V expression, confirmed the
presence of lung tumors 20 wk later, and then induced p38α
down-regulation (Fig. 3B). Interestingly, the down-regulation of
p38α resulted in a significantly decreased number and size of
macroscopic lung tumors in comparison to the tamoxifen-treated
WT mice (Mapk14lox/lox without UBC-Cre-ERT2; Fig. 3C). In-
deed, the number and size of lung tumors in p38α-ΔUb mice were
similar to those in animals analyzed at the initial time point,
prior to tamoxifen injections, suggesting that p38α down-
regulation produced a cytostatic effect. In contrast, WT ani-
mals treated with tamoxifen showed a substantial increase in
both the number of tumors and the average tumor size in com-
parison to the animals analyzed before p38α down-regulation
(Fig. 3C). This indicates that tamoxifen by itself does not in-
terfere with lung tumor growth. As an additional control, we
performed the same experiment using mice bearing UBC-Cre-
ERT2 and Mapk14+/+ alleles and found no significant differ-
ences upon tamoxifen treatment between WT mice and the
Mapk14+/+;UBC-Cre-ERT2 control group in lung tumor number
or in size, ruling out any effect related to the Cre recombinase
activity by itself (SI Appendix, Fig. S2C). Histological analysis of
the tumors showed a remarkable decrease in the percentage of
advanced lesions in p38α-ΔUb mice, with adenocarcinomas being
decreased threefold (Fig. 3D). Collectively, these results further
support the decreased ratio of advanced versus early lesions
observed in p38α-ΔSPC lungs and suggest that KrasG12V-driven
lung tumors are addicted to p38α signaling.
To investigate the cause of the reduced lung tumor load ob-
served upon p38α down-regulation, we performed immunohis-
tochemistry analysis of lung sections. We found that infiltrating
lymphocytes (CD3+), which remained mainly at the periphery of
the tumors, and macrophages (CD68+) were present in similar
numbers in WT and p38α-ΔUb animals. Blood vessel distribution,
as determined by CD31+ staining, was also similar in tumors from
both groups of mice. Likewise, we detected no differences in the
number of apoptotic cells by TUNEL or by cleaved-caspase 3
staining (SI Appendix, Fig. S2 D–F). However, the number of
proliferating cells, as determined by Ki67 immunostaining, was
significantly diminished in lung tumors from p38α-ΔUb mice (Fig.
3E). Therefore, the acute loss of p38α in developing lung tumors
does not alter the numbers of infiltrating immune cells or the
vasculature density, but it impairs cancer cell proliferation and
tumor progression to more advanced stages.
Chemical Inhibition of p38α Reduces Lung Tumor Burden in Mice. The
dependency of lung tumor progression on p38α is a potentially
relevant observation from a clinical perspective. As a proof of
principle, we used the low molecular weight chemical compound
PH797804 to inhibit the kinase activity of p38α. Mice in which
KrasG12V lung tumors had been induced 20 wk before were ad-
ministered either PH797804 or vehicle solution via oral gavage for
14 d. We found that mice treated with the p38α inhibitor showed a
significant decrease in the number and size of lung tumors in
comparison to the vehicle-treated group (Fig. 4A). Inhibition of
p38α signaling in the lungs was confirmed by immunoblotting
analysis of phosphorylation of Hsp27, a downstream target of the
pathway (Fig. 4B). Moreover, we observed that the number and
size of lung tumors in mice treated with PH797804 were similar to
those found before the treatment, suggesting that p38α inhibition
produces a cytostatic effect. In addition, the number of advanced
lesions, as well as the percentage of Ki67+ cells per tumor, were
significantly reduced (Fig. 4 C and D). These results mirror our
observations in p38α-ΔUb mice and show that the role of p38α
promoting lung tumor progression is mediated through its kinase
activity. Moreover, these results suggest that p38α inhibition could
be potentially useful for NSCLC therapy.
Epithelial p38α Is Necessary for the Proliferation of Lung Cancer Cells
in Anchorage-Independent Conditions. To investigate how p38α
contributes to the progression of lung tumors, we tried to induce p38α
deletion in epithelial cells using mice bearing SPC-Cre-ER and
Kras+/FSFG12V alleles, but, since Cre activity was limited to roughly
25% of the AE2 cells (SI Appendix, Fig. S1D and E), the level of p38α
Fig. 2. p38α-ΔSPC mice show increased tumor burden but delayed progression
to advanced stages. (A) Schematic representation of the experimental
treatment regimen. Ad-FlpO, adenovirus expressing FlpO recombinase; TMX,
tamoxifen; i.p., intraperitoneal injection; i.t., intratracheal administration.
(B) Representative images of WT and p38α-ΔSPC lungs stained for the AE2
marker SPC or with Ki67 antibody to detect proliferative cells. (Scale bars,
100 μm.) The histogram shows the quantification of the percentage of Ki67+
cells per tumor (n = 50 WT and n = 47 p38α-ΔSPC tumors from 5 different mice
each). (C) Representative images of WT and p38α-ΔSPC lungs stained with CD45
antibody to estimate the degree of immune cell infiltration. (Scale bars,
100 μm.) The histogram shows the quantification of the CD45+ area as a
percentage of the total area analyzed (n = 30WT and n = 56 p38α-ΔSPC tumors
from 3 different mice each). (D) Representative images of WT and p38α-ΔSPC
lungs stained with H&E. Dot plots show the quantification of the tumor area
(n ≥ 4 mice). (Scale bars, 2 mm.) (E) Tumors were microscopically analyzed and
classified according to their pathological stage as adenocarcinoma (ADC), ad-
enoma (AD), and atypical adenomatous hyperplasia (AAH; n ≥ 4 mice). Data
represent average ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.























knocked-down cells in the tumors was insufficient to draw con-
clusions. Therefore, to study the role of p38α in malignant lung
epithelial cells, we established ex vivo cultures of cancer cells
(named mKLC) isolated from murine KrasG12V lung adenocar-
cinomas (26). We used mice with Mapk14lox/lox alleles so that
Mapk14 can be deleted in the mKLC cells upon Cre recombinase
expression to generate p38α-deficient cells (p38α-ΔmKLC). We
confirmed that mKLC cells expressed the EpCAM epithelial
marker and retained E-cadherin expression upon p38α down-
regulation (SI Appendix, Fig. S3 A and B). We first looked at the
proliferation capacity of the mKLC cells in vitro. Strikingly, we
observed no differences in their cell cycle or their ability to in-
corporate 5-bromo-2′-deoxyuridine (BrdU) when cultured in
standard monolayer conditions (SI Appendix, Fig. S3 C and D).
Similarly, Lewis lung carcinoma (LLC1) murine cells with p38α
down-regulated by shRNAs showed no differences with WT cells
in BrdU incorporation (SI Appendix, Fig. S3 E and F) and had
no growth advantage when injected s.c. into the rare flanks of
nude mice (SI Appendix, Fig. S3G).
Interestingly, when mKLC cells were cultured in soft agar to
mimic tumor growth, we observed that WT and p38α-ΔmKLC
cells formed a similar number of colonies after 20 d in culture
but p38α-ΔmKLC colonies were significantly smaller (Fig. 5A).
In a complementary experiment, we noticed that inducing the
down-regulation of p38α in established colonies formed by
mKLC cells slowed down their growth (SI Appendix, Fig. S3H).
These results were confirmed using H358 human lung cancer
cells, which also formed smaller colonies in soft agar in the
presence of two different p38α chemical inhibitors (SI Appendix,
Fig. S3I).
Consistent with these observations, both WT and p38α-
ΔmKLC cells intratracheally implanted in immunocompetent
mice formed a similar number of lung tumors (Fig. 5 B and C).
However, tumors formed by p38α-ΔmKLC cells showed a signif-
icantly decreased size and less proliferative cells (Fig. 5 C and D).
Likewise, we implanted mKLC cells expressing Cre-ERT2
intratracheally into C57BL/6 mice and, once lung tumors were
formed, p38α down-regulation was induced in vivo. We found
that p38α down-regulation significantly diminished the number
and size of the lung tumors (Fig. 5E), phenocopying the results
observed using the UBC-Cre-ERT2;Kras+/FSFG12V mice. Im-
portantly, these data indicate that the proliferation assays in 2D
cell cultures and s.c. xenografts do not reproduce the in vivo
scenario in lung tumors upon p38α down-regulation. Instead,
p38α signaling appears to have an important contribution to the
proliferation of KrasG12V-driven epithelial lung cancer cells when
these cells are challenged by culturing in anchorage-independent
conditions or by orthotopic implantation in mice.
To further understand the role of p38α in lung tumor pro-
gression, we investigated the effect of p38α depletion on the
metastatic features of mKLC cells. We found that both WT and
p38α-deficient cells showed equivalent adhesion and migration
capacities, resistance to anoikis, and extravasation abilities (SI
Appendix, Fig. S4 A–D). We next confirmed these results by
implanting WT and p38α-ΔmKLC cells into the rare flanks of
immunodeficient mice. The number of lung metastatic foci de-
tected 2 wk after primary tumor resection was similar in both
groups, indicating a similar ability of p38α-ΔmKLC and WT cells
to disseminate and colonize the lung (SI Appendix, Fig. S4E).
However, when we injected LLC1 cells through the tail vein of
Fig. 3. p38α enables KrasG12V-driven lung tumor progression. (A) Representative immunoblots with antibodies to p38α and phospho-p38 (P-p38) of whole
lung lysates from WT and p38α-deficient mice, as indicated by − and + tamoxifen (TMX), respectively, either expressing or not expressing KrasG12V. Tubulin
was used as loading control. Each line corresponds to one mouse. (B) Schematic representation of the experimental treatment regimen. Ad-FlpO, adenovirus
expressing FlpO recombinase; i.p., intraperitoneal injection; i.t., intratracheal administration. (C) Representative images of WT and p38α-ΔUb lungs stained
with H&E. (Scale bars, 2 mm.) Dot plots show the quantification of both the tumor number and the number of tumors bigger than 1 mm in diameter per
animal before (initial) and 2 wk after the TMX treatment in WT and p38α-ΔUb mice (n ≥ 9 mice per group). (D) Tumors as in C were microscopically analyzed
and classified according to their pathological stage as adenocarcinoma (ADC), adenoma (AD), and atypical adenomatous hyperplasia (AAH; n ≥ 6 mice per
group). (E) Representative images of WT and p38α-ΔUb lungs collected 1 wk after TMX injections and stained with Ki67 antibody to detect proliferative cells.
(Scale bars, 100 μm.) The histogram shows the quantification of Ki67+ cells as a percentage of the total number of cells counted per tumor (n = 37 WT and n =
27 p38α-ΔUb tumors from 3 different mice each). Data represent average ± SEM. *P < 0.05, **P < 0.01.

































nude mice, 2 wk later, we observed a smaller lung tumor burden
in animals injected with p38α-deficient cells (SI Appendix, Fig.
S4F). The difference in lung tumor area but not in metastatic
dissemination ability suggests that p38α does not impact on the
metastatic properties of the epithelial lung cancer cells, but
mainly affects their proliferation rate and hence the tumor mass
growth rate.
p38α-Mediated Expression of TIMP-1 Induces Lung Cancer Cell
Proliferation. There is evidence that p38α can regulate both the
expression of cytokines and the transducing signaling pathways
engaged by these factors, which can stimulate cancer cell pro-
liferation (11). Therefore, we analyzed the possibility that se-
creted factors controlled by p38α could self-stimulate the
proliferation of lung cancer cells. We used an antibody array to
check the expression of 40 cytokines in lung tumors formed by
the orthotopic inoculation of either WT or p38α-ΔmKLC cells,
and validated the results in individual tumors by qRT-PCR (SI
Appendix, Fig. S5 A–C). We identified TIMP-1 as one of the
most significantly down-regulated cytokines (Fig. 6A). Moreover,
p38α down-regulation in lung tumors resulted in decreased levels
of Timp1 mRNA (Fig. 6B). Accordingly, TIMP-1 protein levels in
p38α-deficient mouse lungs, either healthy or bearing KrasG12V-
driven tumors, were decreased in comparison to the equivalent WT
lungs (Fig. 6C).
TIMP-1 is an inhibitor of matrix metalloproteinases that can
also promote lung tumor growth through its binding to CD63
(27), and is usually expressed at high levels in lung cancer pa-
tients with poor prognosis (28, 29). Hence, we investigated
whether the reduced Timp1 expression was responsible for the
impaired proliferation of p38α-deficient lung cancer cells. First,
we analyzed Timp1 mRNA levels in epithelial cancer cells sorted
from mouse lung tumors, and observed that Timp1 expression
was dependent on p38α (SI Appendix, Fig. S5D). We also
obtained evidence of TIMP-1 implication in epithelial lung
cancer cell proliferation by using two different TIMP-1 shRNAs,
which reduced the size of colonies formed by mKLC cells grown
in soft agar, an effect that was attenuated in the presence of
recombinant TIMP-1 (Fig. 6 D and E). Moreover, the addition of
recombinant TIMP-1 also rescued the decreased colony size
observed in p38α-deficient mKLC cells grown in soft agar (Fig.
6F). Similar results were observed by adding recombinant TIMP-
1 to human H460 and murine mKLC cells treated with p38α
chemical inhibitors (Fig. 6G and SI Appendix, Fig. S5E). In-
terestingly, analysis of public gene expression databases revealed
a direct correlation between the expression of Timp1 and
MAPK14 mRNAs in human adenocarcinomas (SI Appendix, Fig.
S5F). Therefore, the proliferation of lung cancer epithelial cells
is regulated by the levels of TIMP-1, which, in turn, are
controlled by p38α.
In fact, the p38α regulated transcription factors AP-1 and
ATF-2 have binding sites on the Timp1 promoter, which also
contains two NFκB binding sites (30), and the NFκB pathway has
been shown to control TIMP-1 levels in a mouse lung cancer
model (27). Since TIMP-1 expression controls lung cancer cell
proliferation (Fig. 6E), we hypothesized that inhibition of NFκB
signaling would phenocopy p38α inhibition. Treatment of soft
agar colonies formed by mKLC cells with an inhibitor of IKK2, a
Fig. 4. Chemical inhibition of p38α impairs the growth of KrasG12V-driven lung adenocarcinomas. (A) Representative images of H&E-stained lungs from
animals treated with vehicle or the p38α inhibitor PH797804 (p38i). (Scale bars, 2 mm.) Dot plots show the quantification of both the tumor number and the
number of tumors bigger than 1 mm in diameter per animal before (initial) and after 2 wk of treatment with vehicle or p38i (n ≥ 10 mice per group). (B) Lungs
with tumors from KrasG12V-expressing animals that were administered vehicle or p38i for 15 d, were treated with NaCl ex vivo to hyperactivate the p38α
pathway or left untreated, and then were immunoblotted with the indicated antibodies. Each pair of lines (−, +) corresponds to one mouse. Representative
examples are shown. (C) Tumors were microscopically analyzed and classified according to their pathological stage as adenocarcinoma (ADC), adenoma (AD),
and atypical adenomatous hyperplasia (AAH; n = 3 mice). (D) Representative images of lung tumors from animals treated with vehicle or p38i for 15 d that
were stained with Ki67 antibody to detect proliferative cells. (Scale bars, 100 μm.) The histogram shows the quantification of Ki67+ cells per tumor as a
percentage of the total number of cells counted (n = 70 vehicle- and n = 33 p38i-treated tumors from 4 different mice each). Data represent average ± SEM.
*P < 0.05, **P < 0.01.























kinase upstream of p65 NFκB, resulted in decreased colony size,
which was further decreased by the combined treatment with
both p38α and IKK2 inhibitors (SI Appendix, Fig. S5G). Alto-
gether, these results support a key role for TIMP-1 in Kras-
driven lung cancer, indicating that TIMP-1 promotes epithelial
lung cancer cell proliferation in an autocrine manner, and that
both p38α and NFκB signaling contribute to TIMP-1 production
by epithelial cancer cells.
Discussion
Given the plethora of cellular processes that p38α can regulate,
its role in tumorigenesis has been hard to define. Depending on
the nature of the stimulus, the cell type, and the malignant stage,
p38α is involved in cell death or survival, cell cycle entry, or in-
duction of cell differentiation (11, 31). Therefore, it is difficult to
predict which tumors could benefit from p38α inhibition without
performing in vivo experiments.
Here, we use mouse models of KRAS-driven NSCLC to show
that p38α plays a dual role during lung tumorigenesis. We provide
evidence that p38α plays a tumor-suppressor function in normal
lung epithelial cells, interfering with KrasG12V-driven malignant
transformation. In this case, p38α maintains the homeostasis by
balancing proliferation and differentiation capacities of alveolar
progenitors (9), and maybe also by mediating senescence entry
induced by oncogenic Kras expression, as shown in cultured
fibroblasts (32, 33). Therefore, in the absence of p38α, there is an
increased number of poorly differentiated epithelial cells with the
potential to become tumor-initiating cells (9). In addition to the
deregulated proliferation of the progenitor cells, p38α-deficient
lungs have an enhanced immune response, as indicated by
the increased number of CD45+ cells recruited. These immune
cells probably belong to the myeloid lineage (8), and collat-
erally contribute to tumor-promoting inflammation. Despite
the benefits that the down-regulation of p38α would entail a
priori for tumor development, lung cancer cells do not seem to
shut off this anticancer signaling pathway. Instead, we detect
increased phosphorylated p38α in lung tumors compared to
paired healthy parenchyma, which agrees with previous reports
on NSCLC patients (14–16). Moreover, we show that higher
p38α levels correlate with poor overall survival and with re-
currence in lung adenocarcinoma, as was proposed for co-
lorectal cancer (34). Our results indicate that, during tumor
progression, lung cancer cells take advantage of the ability of
p38α to regulate targets like TIMP-1, a metalloproteinase in-
hibitor that not only regulates extracellular matrix catabolism
but also promotes cell proliferation and survival in an autocrine
manner. This latter function of TIMP-1 is based on both the
regulation of the pericellular availability of protease-dependent
growth factor or cytokine signals and the binding to CD44/pro-
MMP9 or to CD63, which in turn can stimulate ERK, FAK,
Fig. 5. Epithelial p38α is necessary for the proliferation of lung tumor cells. (A) WT and p38α-ΔmKLC cells derived from mouse lung tumors were seeded in soft
agar. Histograms show the number of colonies formed, their average diameter, and the percentage of colonies bigger than 150 μm per well (n ≥ 42 colonies
analyzed). Data represent mean ± SD. (B) Representative images of phospho-MK2 immunostainings of lung tumors formed by intratracheal inoculation of WT
and p38α-ΔmKLC cells. (Scale bars, 100 μm.) (C) Representative images of H&E stained lungs from WT animals that were intratracheally inoculated with either
WT or p38α-ΔmKLC cells. (Scale bars, 2 mm.) Dot plots show the average number of total tumors and the number of tumors with a diameter bigger than 1 mm
at 22 d after the intratracheal inoculation (n ≥ 12 mice per group). Data represent average ± SEM. (D) Representative images of lung tumors from mice that
were intratracheally inoculated with either WT or p38α-ΔmKLC cells and stained with Ki67 antibody. (Scale bars, 100 μm.) The histogram shows the quanti-
fication of Ki67+ cells per tumor as a percentage of the total number of cells counted (n = 55 WT and n = 70 p38α-ΔmKLC tumors each from ≥5 mice). Data
represent average ± SEM. (E) Representative examples of lungs from mice that were intratracheally inoculated with either WT or p38α-ΔmKLC_CRE-ERT2 cells
and, 22 d later, treated with tamoxifen. Lungs were stained with H&E 15 d after p38α down-regulation. (Scale bar, 2 mm.) Dot plots show the quantification
of both the tumor number and the number of tumors bigger than 1 mm in diameter per animal (n = 2 to 6 mice). *P < 0.05, ***P < 0.001. n.s., not significant.

































YAP/TAZ, and PI3K signaling pathways (35, 36). Accordingly,
clinical studies have positively correlated high Timp-1 expression
levels with poor prognosis in lung and colon cancer patients, as
well as with short relapse time and advanced-stage tumors from
breast and brain origin (37).
It has been reported that the IKK2/NFκB and p38 MAPK/ATF-
2 pathways can both induce Timp1 transcription in IL-1–stimulated
human astrocytes, consistent with the presence of AP-1, NFκB,
and ATF-2 binding sites on the Timp1 promoter (30). A previous
study also showed that IKK2 down-regulation decreases tumor cell
proliferation in a mouse model of lung cancer, which correlates
with decreased expression of TIMP-1 (27), mirroring the pheno-
type of p38α down-regulation. Here we show that chemical in-
hibition of either p38α or IKK2 impairs the proliferation of
epithelial lung cancer cells in soft agar. Of note, p38α and NFκB
can coordinately control the expression of several genes, such as
the CXCL10 cytokine (38, 39), which we also found down-
regulated in p38α-deficient lung tumors. In fact, p38α has been
reported to target IκB for degradation (40) and to modulate the
acetylation of p65, hence controlling the transcriptional activity of
NFκB (41). Therefore, it seems likely that both pathways might
perform overlapping functions in lung tumor progression. It would
be interesting to test whether the combined inhibition of p38α and
IKK2 could prevent any compensatory cross-talk and suffice to
trigger lung tumor regression instead of the cytostatic effect ob-
served upon inhibition of either single pathway alone.
Our studies identify p38α as a synthetic lethal interactor of
KrasG12V in lung epithelial cancer cells, suggesting its potential
interest as a therapeutic target. As proof of concept, we used the
p38α pharmacological inhibitor PH797804 that reached phase II
clinical trials for chronic obstructive pulmonary disease (42).
Treatment with PH797804 showed that p38α activity is required
for the progression of genetically induced lung tumors to ad-
vanced stages. In addition, orthotopic xenograft experiments
indicated that epithelial cancer cells rely on p38α signaling to
proliferate within the pulmonary niche in vivo. Although meta-
static properties of lung cancer cells do not seem to depend on
p38α, our results indicate that the malignancy and size of the
lung tumor mass is ultimately determined by the epithelial p38α
levels. This dependency on p38α is highlighted by the anchorage-
independent proliferation assays using lung epithelial cancer
cells ex vivo, and agrees with a report of signet-ring carcinoma
cell lines that also form smaller colonies when treated with the
p38 MAPK inhibitor SB203580 (43). Taken together, our data
Fig. 6. p38α-regulated expression of TIMP-1 induces lung cancer cell proliferation. (A) Relative TIMP-1 protein levels in lung tumors from mice that were
intratracheally inoculated with either WT or p38α-ΔmKLC cells, as determined using a cytokine array (n = 20 tumors from 4 mice per condition analyzed in a
single array). (B) Relative Timp1 mRNA expression in tumors from WT and p38α-ΔUb mice (n = 4 tumors from ≥3 mice per group). (C) Representative im-
munoblots with antibodies to TIMP-1 and tubulin as a loading control of whole lung lysates from WT and p38α-ΔUb mice, as indicated by − and + tamoxifen
(TMX), respectively, either expressing or not expressing the KrasG12V oncogene. Each line corresponds to one mouse. (D) Histogram showing Timp1 down-
regulation in WT mKLC cells treated with shRNAs targeting Timp1 (sh#1 and sh#2) or a nontargeting control (shNT). (E) Representative images of the soft agar
colonies formed by WT mKLC cells treated as in D in the presence or absence of recombinant TIMP-1 protein (rTIMP-1; 0.1 μg/mL) added twice per week. (Scale
bars, 150 μm.) The histogram shows the average colony diameters (n ≥ 52 colonies analyzed per group from 3 replicates). (F) Representative images of the soft
agar colonies formed by WT cells, p38α-ΔmKLC cells, and p38α-ΔmKLC cells treated with rTIMP-1 protein (0.1 μg/mL) twice per week. (Scale bars, 150 μm.) The
histogram shows the average colony diameters (n ≥ 144 colonies analyzed per group from 6 replicates). (G) Average diameters of the colonies formed by the
human NSCLC cell line H460 grown in soft agar for 20 d and treated with vehicle, the p38α inhibitors SB203580 (SB) and PH797804 (PH), or PH plus 0.1 μg/mL
rTIMP-1 protein (≥119 colonies analyzed per group from 3 replicates). Data represent mean ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001. n.s., not significant.























indicate a protumorigenic function of p38α in epithelial cancer
cells of KRAS-driven lung tumors.
There is evidence that p38α can also mediate noncancer cell-
autonomous functions in lung tumors. Ubiquitous expression of a
nonphosphorylatable p38α mutant has been reported to impair the
synthesis of hyaluronic acid by cancer-associated fibroblasts, re-
ducing lung cancer cell proliferation (21). p38α can also regulate
PD-L1 expression in KrasG12V-driven cancer cells, thus impairing
the tumor immunosurveillance capacity (44). Moreover, p38αmight
control the ability of infiltrating myeloid cells to contribute to lung
adenocarcinoma progression, as described in colon cancer via IGF1
production (45). Therefore, p38α seems to control the production
of different extracellular factors that will build autocrine and re-
ciprocal signaling circuitries between stromal and cancer cells, in a
way comparable to the circuitry established by human lung stem
cells and their niche (46). These results support the use of phar-
macological inhibitors of p38α to target protumorigenic functions of
both cancer cells and stromal cells in lung tumors.
Whether the dependency on p38α for lung tumor progression is
restricted to KRAS mutant tumors or applies to other lung tumors
independently of the driver mutation remains to be investigated. In
the case of lung tumors with nonfunctional p53, which account for
about half of NSCLC cases (47), it has been reported that mice
systemically expressing nonphosphorylatable p38α show decreased
KrasG12D-induced tumor burden (21). Moreover, our results using
the human cancer cell lines H460 (p53wt) and H358 (p53-deleted)
suggest that epithelial p38α facilitates soft-agar growth indepen-
dently of the p53 status. It should be also noted that p38α has been
reported to facilitate resistance of lung tumors to cisplatin in vivo in
both p53-proficient and -deficient mouse models (48, 49). There-
fore, the requirement for p38α signaling in cancer cell fitness and in
its interaction with the stroma is likely to represent a selective dif-
ference between normal cells and cancer cells in different tumor
types, which can be exploited to treat lung adenocarcinoma and
perhaps to improve the efficacy of currently used drugs.
Methods
Mice. Kras+/FSFG12V mice (23) were crossed withMapk14lox/lox (9, 50),Mapk14+/−
(51), and UBC-Cre-ERT2 mice (52) to obtain the genotypes Mapk14lox/lox;Ub-
CreERT2;Kras+/FSFG12V and Mapk14lox/−;Ub-CreERT2;Kras+/FSFG12V, which both
gave indistinguishable phenotypes. Kras+/FSFG12VMapk14lox/lox mice were al-
ternatively crossed to Sftpc-Cre-ER mice (53) to obtain mice with lung-specific
p38α down-regulation (p38α-ΔSPC). The two p38α-deficient mouse lines were
on a mixed C57BL/6-FVB background and showed indistinguishable lung
phenotypes, as determined by histology studies. Littermate controls of both
sexes were used in all experiments. Mice were housed according to the na-
tional and European Union regulations, and protocols were approved by the
animal care and use committees of both the Barcelona Science Park (PCB) and
Biomedical Research Park of Barcelona (PRBB).
Generation of mKLC Cells and p38α Down-Regulation Ex Vivo. Primary ade-
nocarcinomas generated in Mapk14lox/lox;Kras+/FSFG12V mice were orthotopi-
cally implanted in Crl:NU-Foxn1nu mice as previously described (26). A freshly
collected fragment of lung tumor was minced with sterile scalpels and then
plated in Dulbecco’s modified Eagle medium (DMEM) supplemented with
20% fetal bovine serum (FBS) plus 1% penicillin/streptomycin. Medium was
renewed once per week until colonies with epithelial cell morphology were
observed. Then, cells were trypsinized and expanded as established cell lines.
To down-regulate p38α, mKLC cells with Mapk14lox/lox alleles were treated
with Tat-Cre recombinant protein (54) at a concentration of 150 μg/mL in
serum-free DMEM with 1% penicillin/streptomycin. After 10 h, medium was
replaced with DMEM 10% FBS, and cells were passaged twice before per-
forming experiments. For mKLC cells carrying both Mapk14lox/lox alleles and
inducible Cre-ERT2, p38α down-regulation was induced by treating with 4OH-
TMX (10 μM; Sigma H6278) for 3 d.
Orthotopic Implantation. Immunocompetent mice were anesthetized and
intratracheally inoculated with 100 μL of a 2 × 106 mKLC cells per milliliter
solution, and tumors were left to grow for 25 d. For intratracheal adminis-
tration, cells were cultured to 70% confluence in DMEM 10% FBS, diluted with
PBS, kept on ice, and thoroughly mixed prior to each inoculation. The vocal
cords were viewed directly with the help of a cold light source, and a blunted
catheter coupled to a syringe was passed beyond them to inoculate the cells.
Histopathological Analysis and Immunohistochemistry.Mouse lungs were fixed
by insufflating 10%neutral buffered formalin (Sigma) through the tracheawith
a syringe, incubated overnight at 4 °C in 10 mL 10% neutral buffered formalin,
and then embedded in paraffin. Tumors in freshly harvested lungs were
counted and sized, and lung sections stained with hematoxylin and eosin (H&E)
were analyzed for tumor grade by two independent observers in a blinded
fashion. Tumor grade was evaluated following established classifications (55).
The human lung cancer tissue array (US Biomax; HLug-Ade050CD-01) included
lung adenocarcinoma samples with adjacent normal tissues and samples of
normal lung from patients without tumor. After staining, it was evaluated
blindly by three independent observers. Slides were incubated using the
following antibodies: CD31 (Abcam no. 28364; 1:500), CD45 (BD Biosciences
no. 550539; 1:100), CD68 (Biorbyt no. 47985; 1:750), cleaved caspase-3 (Cell
Signaling no. 9661; 1:500), Ki67 (Novocastra no. NCL-Ki67p; 1:500), p38α (Cell
Signaling no. 9218; 1:50), phospho-Thr180/Tyr182 p38 MAPK (Cell Signaling
no. 4631; 1:50), phospho-Thr334 MK2 (Cell Signaling no. 3007; 1:100), phospho-
Tyr705 STAT3 (Cell Signaling no. 9145S; 1:200), pro-SPC (Millipore no. AB3786;
1:3,000), and HRP-conjugated secondaries (ImmunoLogic and Dako). Immu-
nostaining was visualized with 3,3-diaminobenzidine and counterstained with
hematoxylin or subsequently incubated with Alexa-conjugated secondary an-
tibodies (Life Technologies A21441; 1:400). To detect apoptosis in paraffin-
embedded samples, the fluorescein in situ cell death detection kit (Roche no.
11684795910) was used according to the manufacturer’s instructions.
Whole digital slides were acquired with a slide scanner (NanoZoomer;
Hamamatsu), and individual images were captured with NDP view software.
All tumors in each tissue section were analyzed. Positive signals were
quantified in an automated manner based on either the relative percentage
of stained surface in a tumor or the relative percentage of positive cells per
tumor using computerized imaging software (ImageJ).
Statistical Methods. Data are presented as means ± SEM unless otherwise in-
dicated. Dataset statistics were analyzed with Prism 7 (GraphPad Software).
Groups were compared using the two-tailed Mann–Whitney test or analysis of
variance (ANOVA; Kruskal–Wallis). P values smaller than 0.05 were considered
statistically significant.
Data Availability. All relevant data, associated protocols, and materials are
within the manuscript and its SI Appendix. Any additional information
needed will be available upon request from the corresponding author.
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